Clinical significance of ErbB receptor family in urothelial carcinoma of the bladder: A systematic review and meta-analysis

Advances in Urology

Volumn , Issue , 2012, Pages

  Tsai, Yuh Shyan ^a   Cheng, Hong Lin ^a   Tzai, Tzong Shin ^a,b   Chow, Nan Haw ^a  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84866983438     PISSN: 16876369     EISSN: 16876377     Source Type: Journal    
DOI: 10.1155/2012/181964     Document Type: Review

References (69)

1. Stenzl A., Cowan N. C., De Santis M., Jakse G., Kuczyk M. A., Merseburger A. S., Ribal M. J., Sherif A., Witjes J. A., The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. European Urology 2009 55 4 815 825 2-s2.0-60249099004 10.1016/j.eururo.2009.01.002
2. Rouprêt M., Zigeuner R., Palou J., Boehle A., Kaasinen E., Sylvester R., Babjuk M., Oosterlinck W., European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. European Urology 2011 59 4 584 594 2-s2.0-79952257273 10.1016/j.eururo.2010.12. 042
3. Heldin C. H., Dimerization of cell surface receptors in signal transduction. Cell 1995 80 2 213 223 2-s2.0-0028838012
4. Pinkas-Kramarski R., Shelly M., Glathe S., Ratzkin B. J., Yarden Y., Neu differentiation factor/neuregulin isoforms activate distinct receptor combinations. Journal of Biological Chemistry 1996 271 32 19029 19032 2-s2.0-0029783549 10.1074/jbc.271.32.19029 (Pubitemid 26271558)
5. Chow N. H., Chan S. H., Tzai T. S., Ho C. L., Liu H. S., Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clinical Cancer Research 2001 7 7 1957 1962 2-s2.0-0034782994
6. Sharma S. V., Bell D. W., Settleman J., Haber D. A., Epidermal growth factor receptor mutations in lung cancer. Nature Reviews Cancer 2007 7 3 169 181 2-s2.0-33847323129 10.1038/nrc2088
7. Lynch T. J., Bell D. W., Sordella R., Gurubhagavatula S., Okimoto R. A., Brannigan B. W., Harris P. L., Haserlat S. M., Supko J. G., Haluska F. G., Louis D. N., Christiani D. C., Settleman J., Haber D. A., Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New England Journal of Medicine 2004 350 21 2129 2139 2-s2.0-2342471392 10.1056/NEJMoa040938 (Pubitemid 38637993)
8. Pritchard K. I., Shepherd L. E., O'Malley F. P., Andrulis I. L., Tu D., Bramwell V. H., Levine M. N., HER2 and responsiveness of breast cancer to adjuvant chemotherapy. New England Journal of Medicine 2006 354 20 2103 2111 2-s2.0-33646681444 10.1056/NEJMoa054504 (Pubitemid 43736610)
9. Slamon D., Eiermann W., Robert N., Pienkowski T., Martin M., Press M., Mackey J., Glaspy J., Chan A., Pawlicki M., Pinter T., Valero V., Liu M. C., Sauter G., von Minckwitz G., Visco F., Bee V., Buyse M., Bendahmane B., Tabah-Fisch I., Lindsay M. A., Riva A., Adjuvant trastuzumab in HER2-positive breast cancer. The New England Journal of Medicine 2011 365 14 1273 1283
10. Freeman M. R., HER2/HER3 heterodimers in prostate cancer: whither HER1/EGFR? Cancer Cell 2004 6 5 427 428 2-s2.0-7944226504 10.1016/j.ccr.2004.10. 018 (Pubitemid 39469975)
11. Blackledge G., Sellers W. R., Smith M. R., Growth factor receptor tyrosine kinase inhibitors; clinical development and potential for prostate cancer therapy. Journal of Urology 2003 170 6 S77 S83 2-s2.0-0242692686 10.1097/01.ju.0000095022.80033.d3 (Pubitemid 37413947)
12. Yan Y., Andriole G. L., Humphrey P. A., Kibel A. S., Patterns of multiple recurrences of superficial (Ta/T1) transitional cell carcinoma of bladder and effects of clinicopathologic and biochemical factors. Cancer 2002 95 6 1239 1246 2-s2.0-0037105465 10.1002/cncr.10822 (Pubitemid 35013058)
13. Chakravarti A., Winter K., Wu C. L., Kaufman D., Hammond E., Parliament M., Tester W., Hagan M., Grignon D., Heney N., Pollack A., Sandler H., Shipley W., Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group. International Journal of Radiation Oncology Biology Physics 2005 62 2 309 317 2-s2.0-21044446131 10.1016/j.ijrobp.2004.09.047 (Pubitemid 40704444)
14. Lipponen P., Eskelinen M., Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. British Journal of Cancer 1994 69 6 1120 1125 2-s2.0-0028302276 (Pubitemid 24161872)
15. Neal D. E., Sharples L., Smith K., Fennelly J., Hall R. R., Harris A. L., The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer 1990 65 7 1619 1625 2-s2.0-0025237455 (Pubitemid 20106125)
16. Kassouf W., Black P. C., Tuziak T., Bondaruk J., Lee S., Brown G. A., Adam L., Wei C., Baggerly K., Bar-Eli M., McConkey D., Czerniak B., Dinney C. P., Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. Journal of Urology 2008 179 1 353 358 2-s2.0-36749029619 10.1016/j.juro.2007.08.087 (Pubitemid 350216717)
17. Pich A., Chiusa L., Formiconi A., Galliano D., Bortolin P., Comino A., Navone R., Proliferative activity is the most significant predictor of recurrence in noninvasive papillary urothelial neoplasms of low malignant potential and grade 1 papillary carcinomas of the bladder. Cancer 2002 95 4 784 790 2-s2.0-0037103038 10.1002/cncr.10733 (Pubitemid 34839670)
18. Têtu B., Fradet Y., Allard P., Veilleux C., Roberge N., Bernard P., Prevalence and clinical significance of HER-2/neu, p53 and Rb expression in primary superficial bladder cancer. Journal of Urology 1996 155 5 1784 1788 2-s2.0-0029871183 10.1016/S0022-5347(01)66198-6 (Pubitemid 26127001)
19. Ravery V., Colombel M., Popov Z., Bastuji S., Patard J. J., Bellot J., Abbou C. C., Fradet Y., Chopin D. K., Prognostic value of epidermal growth factor-receptor, T138 and T43 expression in bladder cancer. British Journal of Cancer 1995 71 1 196 200 2-s2.0-0028896563
20. Popov Z., Gil-Diez-De-Medina S., Ravery V., Hoznek A., Bastuji-Garin S., Lefrere-Belda M. A., Abbou C. C., Chopin D. K., Prognostic value of EGF receptor and tumor cell proliferation in bladder cancer: therapeutic implications. Urologic Oncology 2004 22 2 93 101 2-s2.0-1842735518 10.1016/j.urolonc.2004.01. 001 (Pubitemid 38479801)
21. Gallucci M., Vico E., Merola R., Leonardo C., Sperduti I., Felici A., Sentinelli S., Cantiani R., Orlandi G., Cianciulli A., Adverse genetic prognostic profiles define a poor outcome for cystectomy in bladder cancer. Experimental and Molecular Pathology 2007 83 3 385 391 2-s2.0-36048955430 10.1016/j.yexmp.2007.08.017 (Pubitemid 350087038)
22. Gandour-Edwards R., Lara P. N., Folkins A. K., LaSalle J. M., Beckett L., Li Y., Meyers F. J., DeVere-White R., Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer 2002 95 5 1009 1015 2-s2.0-0036721561 10.1002/cncr.10808 (Pubitemid 34925350)
23. Underwood M., Bartlett J., Reeves J., Gardiner D. S., Scott R., Cooke T., C-erbB-2 gene amplification: a molecular marker in recurrent bladder tumors? Cancer Research 1995 55 11 2422 2430 2-s2.0-0029027518
24. Tsai Y. S., Tzai T. S., Chow N. H., Yang W. H., Tong Y. C., Lin J. S. N., Chang C. C., Cheng H. L., Lin Y. M., Prognostic values of p53 and HER-2/neu coexpression in invasive bladder cancer in Taiwan. Urologia Internationalis 2003 71 3 262 270 2-s2.0-0141649419 10.1159/000072676 (Pubitemid 37186741)
25. Haitel A., Posch B., El-Baz M., Mokhtar A. A., Susani M., Ghoneim M. A., Marberger M., Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2. Journal of Urology 2001 165 5 I 1481 1487 2-s2.0-0035043436 (Pubitemid 32410219)
26. Khaled H. M., Bahnassy A. A., Raafat A. A., Zekri A. R. N., Madboul M. S., Mokhtar N. M., Clinical significance of altered nm23-H1, EGFR, RB and p53 expression in bilharzial bladder cancer. BMC Cancer 2009 9, article 32 2-s2.0-63049112093 10.1186/1471-2407-9-32
27. Liedberg F., Anderson H., Chebil G., Gudjonsson S., Höglund M., Lindgren D., Lundberg L. M., Lövgren K., Fernö M., Månsson W., Tissue microarray based analysis of prognostic markers in invasive bladder cancer: much effort to no avail? Urologic Oncology 2008 26 1 17 24 2-s2.0-37649024111 10.1016/j.urolonc.2006.08.021
28. Memon A. A., Sorensen B. S., Meldgaard P., Fokdal L., Thykjaer T., Nexo E., The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients. British Journal of Cancer 2006 94 11 1703 1709 2-s2.0-33745272244 10.1038/sj.bjc.6603154 (Pubitemid 43924936)
29. Thogersen V. B., Sorensen B. S., Poulsen S. S., Orntoft T. F., Wolf H., Nexo E., A subclass of HER1 ligands is a prognostic marker for survival in bladder cancer patients. Cancer Research 2001 61 16 6227 6233 2-s2.0-0035881981 (Pubitemid 32762561)
30. Lonn U., Lonn S., Friberg S., Nilsson B., Silfversward C., Stenkvist B., Prognostic value of amplification of c-erb-B2 in bladder carcinoma. Clinical Cancer Research 1995 1 10 1189 1194 2-s2.0-0028883362
31. Miyamoto H., Kubota Y., Noguchi S., Takase K., Matsuzaki J., Moriyama M., Takebayashi S., Kitamura H., Hosaka M., C-erbB-2 gene amplification as a prognostic marker in human bladder cancer. Urology 2000 55 5 679 683 2-s2.0-0034185043
32. Simon R., Atefy R., Wagner U., Forster T., Fijan A., Bruderer J., Wilber K., Mihatsch M. J., Gasser T., Sauter G., HER-2 and TOP2A coamplification in urinary bladder cancer. International Journal of Cancer 2003 107 5 764 772 2-s2.0-10744229554 10.1002/ijc.11477 (Pubitemid 37339730)
33. Jimenez R. E., Hussain M., Bianco F. J., Vaishampayan U., Tabazcka P., Sakr W. A., Pontes J. E., Wood D. P., Grignon D. J., Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clinical Cancer Research 2001 7 8 2440 2447 2-s2.0-0034890387 (Pubitemid 32751647)
34. Kolla S. B., Seth A., Singh M. K., Gupta N. P., Hemal A. K., Dogra P. N., Kumar R., Prognostic significance of Her2/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy. International Urology and Nephrology 2008 40 2 321 327 2-s2.0-52649176386 10.1007/s11255-007-9283-x
35. Krüger S., Weitsch G., Büttner H., Matthiensen A., Böhmer T., Marquardt T., Sayk F., Feller A. C., Böhle A., HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications. International Journal of Cancer 2002 102 5 514 518 2-s2.0-0037058715 10.1002/ijc.10731 (Pubitemid 35316007)
36. Krüger S., Mahnken A., Kausch I., Feller A. C., Value of clusterin immunoreactivity as a predictive factor in muscle-invasive urothelial bladder carcinoma. Urology 2006 67 1 105 109 2-s2.0-30344434661 10.1016/j.urology.2005. 04.043 (Pubitemid 43069266)
37. Sato K., Moriyama M., Mori S., Saito M., Watanuki T., Terada K., Okuhara E., Akiyama T., Toyoshima K., Yamamoto T., Kato T., An immunohistologic evaluation of c-erbB-2 gene product in patients with urinary bladder carcinoma. Cancer 1992 70 10 2493 2498 2-s2.0-0026486874 10.1002/1097-0142(19921115)70: 102493::AID-CNCR2820701017>3.0.CO;2-K
38. Wong Y. L. S., Plimack E. R., Vaughn D. J., Song W, Cohen Sm, Lee JW, Dabrow MD, Tuttle H, Hudes GR., Effect of EGFR inhibition with cetuximab on the efficacy of paclitaxel in previously treated metastatic urothelial cancer. Journal of Clinical Oncology 2011 29 supplement 7, abstract 243
39. Philips G. K., Halabi S., Sanford B. L., Bajorin D., Small E. J., A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102. British Journal of Urology International 2008 101 1 20 25 2-s2.0-36849022660 10.1111/j.1464-410X.2007.07226.x (Pubitemid 350233568)
40. Philips G. K., Halabi S., Sanford B. L., Bajorin D., Small E. J., A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102. Annals of Oncology 2009 20 6 1074 1079 2-s2.0-66149084012 10.1093/annonc/mdn749
41. Petrylak D. P., Tangen C. M., Van Veldhuizen P. J., Goodwin J. W., Twardowski P. W., Atkins J. N., Kakhil S. R., Lange M. K., Mansukhani M., Crawford E. D., Results: of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium. British Journal of Urology International 2010 105 3 317 321 2-s2.0-75149171017 10.1111/j.1464-410X.2009.08799.x
42. Wülfing C., Machiels J. P. H., Richel D. J., Grimm M. O., Treiber U., De Groot M. R., Beuzeboc P., Parikh R., Pétavy F., El-Hariry I. A., A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer 2009 115 13 2881 2890 2-s2.0-67649579849 10.1002/cncr.24337
43. Choueiri T. K., Ross R. W., Jacobus S., Vaishampayan U., Yu E. Y., Quinn D. I., Hahn N. M., Hutson T. E., Sonpavde G., Morrissey S. C., Buckle G. C., Kim W. Y., Petrylak D. P., Ryan C. W., Eisenberger M. A., Mortazavi A., Bubley G. J., Taplin M.-E., Rosenberg J. E., Kantoff P. W., Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. Journal of Clinical Oncology 2012 30 5 507 512 2-s2.0-84856851592 10.1200/JCO.2011.37.7002
44. Heimberg M., Weinstein I., LeQuire V. S., Cohen S., The induction of fatty liver in neonatal animals by a purified protein (EGF) from mouse submaxillary gland. Life Sciences 1965 4 17 1625 1633 2-s2.0-0013796898
45. Cohen S., Carpenter G., King L., Epidermal growth factor-receptor-protein kinase interactions. Co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity. Journal of Biological Chemistry 1980 255 10 4834 4842 2-s2.0-0019332558
46. Neal D. E., Smith K., Fennelly J. A., Bennett M. K., Hall R. R., Harris A. L., Epidermal growth factor receptor in human bladder cancer: a comparison of immunohistochemistry and ligand binding. Journal of Urology 1989 141 3 I 517 521 2-s2.0-0024557145 (Pubitemid 19089139)
47. Chow N. H., Liu H. S., Lee E. I. C., Chang C. J., Chan S. H., Cheng H. L., Tzai T. S., Lin J. S. N., Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer. Anticancer Research 1997 17 2B 1293 1296 2-s2.0-0030980531
48. Mattila A. L., Perheentupa J., Pesonen K., Viinikka L., Epidermal growth factor in human urine from birth to puberty. Journal of Clinical Endocrinology and Metabolism 1985 61 5 997 1000 2-s2.0-0022387798 (Pubitemid 16218505)
49. Stromberg K., Duffy M., Fritsch C., Hudgins W. R., Sharp E. S., Murphy L. D., Lippman M. E., Bates S. E., Comparison of urinary transforming growth factor-alpha in women with disseminated breast cancer and healthy control women. Cancer Detection and Prevention 1991 15 4 277 283 2-s2.0-0026294195
50. Ullrich A., Schlessinger J., Signal transduction by receptors with tyrosine kinase activity. Cell 1990 61 2 203 212 2-s2.0-0025343230 10.1016/0092-8674(90)90801-K (Pubitemid 20149352)
51. Lemmon M. A., Schlessinger J., Cell signaling by receptor tyrosine kinases. Cell 2010 141 7 1117 1134 2-s2.0-77953896432 10.1016/j.cell.2010.06.011
52. Olayioye M. A., Neve R. M., Lane H. A., Hynes N. E., The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO Journal 2000 19 13 3159 3167 2-s2.0-0034600849 (Pubitemid 30428195)
53. Olayioye M. A., Graus-Porta D., Beerli R. R., Rohrer J., Gay B., Hynes N. E., ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner. Molecular and Cellular Biology 1998 18 9 5042 5051 2-s2.0-0031840484 (Pubitemid 28388087)
54. Yoshida J., Ishibashi T., Nishio M., Growth-inhibitory effect of a streptococcal antitumor glycoprotein on human epidermoid carcinoma A431 cells: involvement of dephosphorylation of epidermal growth factor receptor. Cancer Research 2001 61 16 6151 6157 2-s2.0-0035881571 (Pubitemid 32762552)
55. Qiu X. B., Goldberg A. L., Nrdp1/FLRF is a ubiquitin ligase promoting ubiquitination and degradation of the epidermal growth factor receptor family member, ErbB3. Proceedings of the National Academy of Sciences of the United States of America 2002 99 23 14843 14848 2-s2.0-0037069388 10.1073/pnas. 232580999 (Pubitemid 35334571)
56. Alwan H. A. J., Van Zoelen E. J. J., Van Leeuwen J. E. M., Ligand-induced lysosomal epidermal growth factor receptor (EGFR) degradation is preceded by proteasome-dependent EGFR de-ubiquitination. Journal of Biological Chemistry 2003 278 37 35781 35790 2-s2.0-0041816011 10.1074/jbc.M301326200 (Pubitemid 37102355)
57. Hackel P. O., Zwick E., Prenzel N., Ullrich A., Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Current Opinion in Cell Biology 1999 11 2 184 189 2-s2.0-0032915392 10.1016/S0955-0674(99)80024-6 (Pubitemid 29164032)
58. Marks J. L., McLellan M., Zakowski M. F., Lash A. E., Kasai Y., Broderick S., Sarkaria I. S., Pham D., Singh B., Miner T. L., Fewell G. A., Fulton L. L., Mardis E. R., Wilson R. K., Kris M. G., Rusch V. W., Varmus H., Pao W., Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4. PLoS ONE 2007 2 5, article e426 2-s2.0-34547730818 10.1371/journal.pone.0000426
59. Nieto Y., Nawaz F., Jones R. B., Shpall E. J., Nawaz S., Prognostic significance of overexpression and phosphorylation of Epidermal Growth Factor Receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advanced breast cancer. Journal of Clinical Oncology 2007 25 28 4405 4413 2-s2.0-35348848403 10.1200/JCO.2006.09.8822 (Pubitemid 350013846)
60. Akslen L. A., Puntervoll H., Bachmann I. M., Straume O., Vuhahula E., Kumar R., Molven A., Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma. Melanoma Research 2008 18 1 29 35 2-s2.0-42449147592 10.1097/CMR. 0b013e3282f32517 (Pubitemid 351628053)
61. Peraldo-Neia C., Migliardi G., Mello-Grand M., Montemurro F., Segir R., Pignochino Y., Cavalloni G., Torchio B., Mosso L., Chiorino G., Aglietta M., Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer. BMC Cancer 2011 11, article 31 2-s2.0-78951472024 10.1186/1471-2407-11-31
62. Latif Z., Watters A. D., Dunn I., Grigor K. M., Underwood M., Bartlett J., HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder. British Journal of Cancer 2003 89 7 1305 1309 2-s2.0-0242266485 10.1038/sj.bjc.6601245 (Pubitemid 37363421)
63. Avraham R., Yarden Y., Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nature Reviews Molecular Cell Biology 2011 12 2 104 117 2-s2.0-78951489049 10.1038/nrm3048
64. Amsellem-Ouazana D., Beuzeboc P., Peyromaure M., Viellefond A., Zerbib M., Debre B., Management of primary resistance to gemcitabine and cisplatin (G-C) chemotherapy in metastatic bladder cancer with HER2 over-expression. Annals of Oncology 2004 15 3 538 2-s2.0-1842450734 10.1093/annonc/mdh112
65. Tsai Y. S., Tzai T. S., Chow N. H., Does HER2 immunoreactivity provide prognostic information in locally advanced urothelial carcinoma patients receiving adjuvant M-VEC chemotherapy? Urologia Internationalis 2007 79 3 210 216 2-s2.0-35348900030 10.1159/000107952 (Pubitemid 47586928)
66. Puppo P., Conti G., Francesca F., Mandressi A., Naselli A., New Italian guidelines on bladder cancer, based on the World Health Organization 2004 classification. British Journal of Urology International 2010 106 2 168 179 2-s2.0-77953854791 10.1111/j.1464-410X.2010.09324.x
67. Stenzl A., Cowan N. C., De Santis M., Kuczyk M. A., Merseburger A. S., Ribal M. J., Sherif A., Witjes J. A., Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. European Urology 2011 59 6 1009 1018 2-s2.0-79955629384 10.1016/j.eururo.2011.03.023
68. Laupacis A., Wells G., Richardson W. S., Tugwell P., Guyatt G. H., Browman G., Cook D., Gerstein H., Haynes B., Hayward R., Levine M., Nishikawa J., Sackett D. L., Brill-Edwards P., Farkouh M., Holbrook A., Jaeschke R., Lee H., Sauve S., Users' guides to the medical literature: V. How to use an article about prognosis. Journal of the American Medical Association 1994 272 3 234 237 2-s2.0-0028291009 10.1001/jama.272.3.234 (Pubitemid 24209087)
69. Malats N., Bustos A., Nascimento C. M., Fernandez F., Rivas M., Puente D., Kogevinas M., Real F. X., P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncology 2005 6 9 678 686 2-s2.0-24044554230 10.1016/S1470-2045(05)70315-6 (Pubitemid 41222758)